Najlepsi lekarze wykonujący MRI całego ciała w Izraelu – TOP 12 lekarzy

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.

She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.

Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

Dr Oren Shibolet jest doświadczonym gastroenterologiem i hematologiem z ponad 50-letnią praktyką. Jest wiodącym ekspertem w zakresie chorób wątroby i ich leczenia, pełniąc funkcję Kierownika Oddziału Chorób Wątroby w Centrum Medycznym Sourasky (Ichilov). Posiada dyplom z medycyny ogólnej Uniwersytetu Hebrajskiego, specjalizację z gastroenterologii z Wydziału Medycznego Uniwersytetu Hebrajskiego Hadassah i jest członkiem wielu organizacji medycznych. Jest również autorem ponad 60 publikacji i 100 raportów konferencyjnych.

• Edukacja
• 1992-1999 - Wydział Medycyny, Technion.
• Specjalizacja
• 2000-2005 - Staż w Instytucie Wizualizacji, Medyczne Centrum Tel Aviv Sourasky (Ichilov).
• Uznane doświadczenie
• Radiologia diagnostyczna
• Podspecjalizacja:
• 2005-2007 - Obrazowanie piersi, Instytut Mammografii, Centrum Medyczne Tel Aviv.
• Dodatkowa edukacja
• 2008 - Rezonans magnetyczny gruczołu piersiowego, staż w Centrum Medycznym Instytutu Curie, Paryż, Francja.
• 2012 - Okres szkolenia w zakresie zaawansowanych technologii obrazowania piersi w Centrum Onkologicznym Gustave Roussy, Villejuif, Francja.
• 2009,2011,2013 - Zaktualizowane kursy dotyczące wizualizacji piersi.
• Doświadczenie kliniczne
• 2013 - Dyrektor Departamentu Mammografii, Centrum Medyczne w Tel Awiwie.
• 2007 - Konsultant ds. obrazowania piersi w Maccabi HMO.
• 2005 - Starszy lekarz, Centrum Medyczne Sourasky, Tel Awiw.
• 2000-2005 - Staż w Instytucie Wizualizacji, Centrum Medyczne Sourasky, Tel Awiw.
• 1999-2000 - Staż, Centrum Medyczne Sheba.
• Doświadczenie akademickie
• 2010- Szkolenie z zakresu obrazowania piersi dla studentów medycyny na latach klinicznych, Wydział Obrazowania, Wydział Medycyny, Uniwersytet Tel Awiw.
• 2013 - Wykładowca dla chirurgów stażystów, Szkoła Kształcenia Ustawicznego, Szkoła Medycyny, Uniwersytet Tel Awiw.
• 2000-2005 - Wykładowca w Szkole Radiografii, Centrum Medyczne Sourasky, Tel Awiw, Uniwersytet Bar-Ilan.
• Członkostwo w związkach zawodowych
• Izraelskie Stowarzyszenie Radiologów
• Departament Obrazowania Piersi
• Izraelskie Stowarzyszenie Medyczne
• Północnoamerykańskie Stowarzyszenie Radiologii.
• Obszary szczególnego zainteresowania i działalności
• Biopsja piersi i przedoperacyjne oznakowanie z użyciem MRI.
• Wizualizacja piersi w automatycznym 3D ultradźwięków.
• Usuwanie guzków piersi przy użyciu nieinwazyjnej technologii radiowej (BLES).
• Mammografia z wprowadzeniem środka kontrastowego.
• Molekularne Obrazowanie Piersi, MBI (Molecular Breast Imaging)

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Dr. Boaz Liberman, MD, is an orthopedic oncologist and sarcoma surgeon for adults and children. He directs the Orthopedic Oncology Unit and serves as Vice Head of Orthopedic Surgery at Sheba Medical Center. His focus is limb-sparing cancer surgery with functional reconstruction. He performs complex joint reconstruction, revision arthroplasty, MRgFUS, and reconstruction after bone metastases.

Education and training: MD, Tel Aviv University. Orthopedic surgery residency, Sheba Medical Center. Fellowships in Adult Reconstruction at Mount Sinai Hospital, Toronto, and in Orthopedic Oncology at Mount Sinai Hospital and Princess Margaret Cancer Centre. He is board-certified in Orthopedic Surgery and in Orthopedic Oncology Surgery. He is a Clinical Instructor at Tel Aviv University. Memberships include the Israel Medical Association, Israel Orthopedic Association, AATB, and EATB. He also serves on national advisory committees. His research covers bone and soft tissue sarcomas, serum markers, imaging-guided therapies, MRI arthrography, and the biomechanics of bone treated with MRgFUS.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Prof. Elad Jacoby, MD

Global Leader in Pediatric Hemato-Oncology, CAR-T Therapy & Bone Marrow Transplantation

About Prof. Elad Jacoby

Prof. Elad Jacoby is one of the world’s leading experts in pediatric hemato-oncology and advanced cellular therapies, serving as the Head of the Pediatric Cell Therapy Center and Medical Director of the Advanced Biotherapy Center at Sheba Medical Center. With nearly two decades of clinical and research experience, he is widely recognized for transforming the treatment landscape for children with complex and treatment-resistant blood cancers.

Prof. Jacoby is a pioneer of CAR-T cell therapy in Israel, having led the implementation of one of the first national programs for pediatric leukemia. His work focuses on delivering highly personalized, cutting-edge therapies to children who often have limited or no remaining standard treatment options.

Beyond his clinical leadership, he is an Associate Professor at Tel Aviv University, actively involved in training the next generation of physicians while leading groundbreaking international research in immunotherapy and cellular medicine.

Clinical Expertise & Special Focus

Prof. Jacoby specializes in the most advanced and life-saving treatments for children and young patients with hematologic malignancies, including:

• CAR-T Cell Therapy (Chimeric Antigen Receptor T-Cells)
  Personalized immunotherapy designed to reprogram the patient’s immune system to fight cancer
• Bone Marrow & Stem Cell Transplantation (BMT)
  Including complex and high-risk transplant cases
• Pediatric Leukemia & Lymphoma
  Acute lymphoblastic leukemia (ALL), relapsed/refractory leukemias, and aggressive lymphomas
• Advanced Cellular Immunotherapy
  Including anti-viral T-cell therapies for immunocompromised patients
• Mitochondrial Augmentation Therapy (MAT)
  First-in-human innovative treatments for rare and complex conditions

His approach combines precision medicine, immunotherapy, and transplantation, allowing for comprehensive, individualized care even in the most challenging cases.

Innovation & Research Leadership

Prof. Jacoby is at the forefront of global innovation in pediatric cancer care. He leads and participates in international clinical trials focused on next-generation therapies, including:

• CAR-T therapies for resistant leukemias and lymphomas
• Novel cellular therapies targeting cancer and severe infections
• Breakthrough research in mitochondrial medicine and immune system modulation

He has authored over 240 scientific publications in leading medical journals and collaborates with top institutions worldwide, including:

• Johns Hopkins Hospital (USA)
• National Cancer Institute (NCI), USA
• International pediatric oncology and CAR-T research networks

His research directly translates into real-world treatment options, giving patients access to therapies not widely available elsewhere.

Patient-Centered Approach

Prof. Jacoby is known not only for his clinical excellence but also for his deep commitment to patient-centered care. Every child and family receives:

• A fully personalized treatment plan tailored to the disease and patient profile
• Access to the most advanced therapies available globally
• Close monitoring by a multidisciplinary team of experts
• Compassionate guidance throughout every stage of treatment

His philosophy is simple: combine innovation with empathy, ensuring that families feel supported, informed, and confident in their care journey.

Leadership & Roles

• Head, Pediatric Cell Therapy Center, Sheba Medical Center
• Medical Director, Advanced Biotherapy Center, Sheba Medical Center
• Senior Lecturer / Associate Professor, Tel Aviv University School of Medicine
• Member, CAR-T Cell Taskforce (IBFM Study Group)
• Member, Institutional Review Board, Sheba Medical Center

Education & International Training

• MD, Tel Aviv University School of Medicine
• Pediatrics Residency, Sheba Medical Center
• Fellowship in Pediatric Hematology & Oncology, Johns Hopkins Hospital, USA
• Clinical & Research Fellowship, National Cancer Institute (NCI), USA

Board Certifications

• Pediatrics
• Pediatric Hematology & Oncology

Why Patients Choose Prof. Elad Jacoby

• Pioneer of pediatric CAR-T therapy in Israel
• Leader in integrating CAR-T with bone marrow transplantation
• Access to exclusive clinical trials and next-generation treatments
• Extensive experience in complex and relapsed cases
• Internationally recognized expert with a strong academic and research background
• Dedicated to delivering hope through innovation and personalized care

A Leader in the Future of Pediatric Cancer Care

Through his work, Prof. Jacoby continues to redefine what is possible in treating childhood cancers—bringing together science, innovation, and compassionate care to improve outcomes and give new hope to patients and their families worldwide.